Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543510 | 0.98 | SLC16A3 (0.41) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL5542952 | 0.98 | SLC16A3 (0.41) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL5540320 | 0.95 | MTNR1A (0.43) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL25888 | 0.88 | MTNR1A (0.45) | MTNR1ANQO2NPC1RAB9ATDP1 | |
| SCHEMBL9800436 | 0.80 | CYP1A2 (0.58) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL5013370 | 0.78 | CYP1A2 (0.46) | MTNR1ANQO2GPR84TDP1CYP1A2 | |
| SCHEMBL5013367 | 0.78 | NQO2 (0.45) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL3225216 | 0.78 | MTNR1A (0.45) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL29853 | 0.78 | NPC1 (0.54) | NPC1RAB9ATDP1CYP1A2CYP2C9 | |
| SCHEMBL5538679 | 0.77 | MTNR1A (0.42) | MTNR1ANQO2GPR84TDP1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20030144249-A1 | Use of organophosphorous compounds for producing a medicament for treating infections | JOMAA PHARMAKA GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4054571-A | Nitrogen-containing polycyclic compounds and a process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144249-A1 | Use of organophosphorous compounds for producing a medicament for treating infections | PHPT1, PPM1D, BPNT1 | MTNR1A 645/4885NQO2 1653/4885NPC1 1282/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MTNR1A 1560/4885NQO2 123/4885NPC1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.